RxDoctor Payments Data

Reneita Ross, MD

Gynecology · Philadelphia, PANPI 1528091410

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 75.5% of it on its own, with 10 other manufacturers making up the rest. Among gynecology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,950in general payments, 2019–2025

Across 199 payments — averaging $39.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$286
  • AbbVie$217
  • Urovant Sciences Inc$147
  • Coloplast$82
  • plus $214 from 5 others

What the payments were for

  • Food & beverage$7,58095%
  • Education$3705%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,950 in reported general payments places this provider in the 90th percentile of 98 gynecology providers in Pennsylvania.

See all gynecology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$42,562
Medicare patients
104
Services billed
432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron141$88,907
GemtesaVibegron62$42,666
Estradiol87$4,861
Solifenacin Succinate70$1,104
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst59$629
Clobetasol Propionate20$331
Tolterodine Tartrate ErTolterodine Tartrate11$222
Hydroxyzine Hcl14$201
Gabapentin19$195
Ciprofloxacin Hcl27$158
Amitriptyline Hcl14$110
Fluconazole16$95
Oxycodone Hcl18$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,005$88,907141 claims
Sumitomo Pharma America, Inc.Gemtesa$286$42,66662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 98 gynecology providers in Pennsylvania.

Other gynecology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →